2021
A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer
Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 110: 1423-1431. PMID: 33677053, DOI: 10.1016/j.ijrobp.2021.02.055.Peer-Reviewed Original ResearchConceptsStage IIIC endometrial carcinomaOverall survivalEndometrial carcinomaRadiation therapyAdjuvant chemotherapyAdjuvant therapyPALN recurrenceSystemic chemotherapyRFS ratesMulti-institutional retrospective cohort studyStage IIIC endometrial cancerRecurrence-free survival ratesLymph node recurrenceSequential radiation therapyAdjuvant radiation therapyRetrospective cohort studyGrade 3 tumorsAdjuvant treatment regimensKaplan-Meier methodVaginal cuff brachytherapyHigh rateSequence of treatmentChemotherapy concurrentNodal radiationNode recurrence
2020
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study
Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemoradiotherapy, AdjuvantCystadenocarcinoma, SerousFemaleFollow-Up StudiesHumansHysterectomyImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisProgression-Free SurvivalReceptor, ErbB-2Retrospective StudiesRisk AssessmentUnited StatesUterine NeoplasmsUterusConceptsHuman epidermal growth factor 2Uterine serous carcinomaHER2-positive tumorsEarly-stage diseaseOverall survivalSerous carcinomaCohort studyHER2 positivityPositive tumorsEarly stage uterine serous carcinomaLymph-vascular space invasionRecurrent uterine serous carcinomaMulti-institutional cohort studyHuman epidermal growth factor receptor 2Multi-center cohort studyEpidermal growth factor receptor 2Epidermal growth factor 2HER2-positive cohortGrowth factor receptor 2HER2-negative tumorsEquivocal IHC resultsFactor receptor 2Inferior PFSAdjuvant therapyGrowth factor 2
2018
Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy
Stahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, Park HS, Damast S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Supportive Care In Cancer 2018, 27: 1425-1433. PMID: 30187220, DOI: 10.1007/s00520-018-4441-5.Peer-Reviewed Original ResearchConceptsVaginal stenosisEndometrial carcinomaMultivariable Cox proportional hazardsMultivariable Cox regression analysisVD useAcademic tertiary referral centerTertiary referral centerCox regression analysisLog-rank testCox proportional hazardsDevelopment of gradeDilator usePelvic radiotherapyReferral centerNoncompliant patientsPrimary outcomeAdjuvant brachytherapyEC patientsConclusionsThe riskRate brachytherapyProportional hazardsOptimal durationPatientsBrachytherapyStudy period
2015
Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma
Park HS, Ratner ES, Lucarelli L, Polizzi S, Higgins SA, Damast S. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy 2015, 14: 464-470. PMID: 25887343, DOI: 10.1016/j.brachy.2015.03.001.Peer-Reviewed Original ResearchConceptsVaginal stenosisDilator useIndependent predictorsEndometrial carcinomaTotal doseRate brachytherapyMultivariable logistic regression analysisExternal beam radiation therapyCommon Terminology CriteriaEffective adjuvant treatmentMonths of followupPost-treatment factorsBeam radiation therapyHigher total doseLogistic regression analysisTerminology CriteriaAdjuvant treatmentFollowup visitMean followupAdverse eventsLast followupMultivariable analysisRisk factorsRadiation therapyPatients
2014
Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer
Damast S, Alektiar K, Eaton A, Gerber NK, Goldfarb S, Patil S, Jia R, Leitao M, Carter J, Basch E. Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer. Annals Of Surgical Oncology 2014, 21: 2740-2754. PMID: 24619493, DOI: 10.1245/s10434-014-3562-4.Peer-Reviewed Original ResearchConceptsFemale Sexual Function IndexPoor health statesSexual functioningEndometrial cancerSexual functionEarly-stage endometrial cancerHealth statesStage I endometrial cancerBaseline sexual activityStage endometrial cancerEndometrial cancer survivorsSexual Function IndexSignificant risk factorsSurgery groupUnderwent surgeryEQ5D scoresFSFI scoreSurgery typeAdjuvant brachytherapyCancer survivorsMore frequent useRisk factorsFunction IndexSexual dysfunctionMultivariable regression
2012
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer
Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer. Gynecologic Oncology 2012, 127: 321-325. PMID: 22850412, DOI: 10.1016/j.ygyno.2012.07.112.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarboplatinChemoradiotherapy, AdjuvantCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Administration ScheduleEndometrial NeoplasmsFemaleFollow-Up StudiesHumansHysterectomyMiddle AgedNeoplasm StagingOvariectomyPaclitaxelRetrospective StudiesSalpingectomySurvival AnalysisTreatment OutcomeConceptsCarboplatin/paclitaxel chemotherapyUterine papillary serous carcinomaPaclitaxel chemotherapyStage IEarly-stage uterine papillary serous carcinomaPapillary serous endometrial cancerParaaortic lymph node samplingDistant recurrence ratesMedian patient ageStage II diseaseFive-year outcomesLymph node samplingKaplan-Meier methodOverall survival ratePapillary serous carcinomaSingle institution experienceLog-rank testSerous endometrial cancerConcurrent carboplatinMedian followPelvic radiationOmental biopsyPara-aorticPelvic recurrenceUnderwent surgery
2010
Impact of Dose on Local Failure Rates After Image-Guided Reirradiation of Recurrent Paraspinal Metastases
Damast S, Wright J, Bilsky M, Hsu M, Zhang Z, Lovelock M, Cox B, Zatcky J, Yamada Y. Impact of Dose on Local Failure Rates After Image-Guided Reirradiation of Recurrent Paraspinal Metastases. International Journal Of Radiation Oncology • Biology • Physics 2010, 81: 819-826. PMID: 20888133, DOI: 10.1016/j.ijrobp.2010.06.013.Peer-Reviewed Original ResearchConceptsImage-guided intensity-modulated radiotherapyLocal failure rateParaspinal metastasisImpact of doseDaily fractionsIncidence of myelopathySingle-fraction regimensRecords of patientsRisk of myelopathyIntensity-modulated radiotherapyCumulative incidenceEpidural diseaseField recurrenceDose groupProspective dataFailure rateTreatment characteristicsLF incidenceMetastasisIncidenceSignificant decreaseGyMyelopathyDoseIg